Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.14
ENDP's Cash to Debt is ranked lower than
58% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. ENDP: 0.14 )
ENDP' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 0.14

Equity to Asset 0.08
ENDP's Equity to Asset is ranked lower than
60% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. ENDP: 0.08 )
ENDP' s 10-Year Equity to Asset Range
Min: 0.08   Max: 0.76
Current: 0.08

0.08
0.76
F-Score: 5
Z-Score: 0.98
M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) -16.26
ENDP's Operating margin (%) is ranked higher than
51% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. ENDP: -16.26 )
ENDP' s 10-Year Operating margin (%) Range
Min: -19.18   Max: 38.19
Current: -16.26

-19.18
38.19
Net-margin (%) -26.19
ENDP's Net-margin (%) is ranked higher than
50% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. ENDP: -26.19 )
ENDP' s 10-Year Net-margin (%) Range
Min: -79.44   Max: 24.67
Current: -26.19

-79.44
24.67
ROE (%) -130.29
ENDP's ROE (%) is ranked lower than
58% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ENDP: -130.29 )
ENDP' s 10-Year ROE (%) Range
Min: -130.29   Max: 23.99
Current: -130.29

-130.29
23.99
ROA (%) -10.43
ENDP's ROA (%) is ranked higher than
51% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. ENDP: -10.43 )
ENDP' s 10-Year ROA (%) Range
Min: -33.52   Max: 15.13
Current: -10.43

-33.52
15.13
ROC (Joel Greenblatt) (%) -30.01
ENDP's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. ENDP: -30.01 )
ENDP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -127.44   Max: 824.32
Current: -30.01

-127.44
824.32
Revenue Growth (%) 16.70
ENDP's Revenue Growth (%) is ranked higher than
81% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. ENDP: 16.70 )
ENDP' s 10-Year Revenue Growth (%) Range
Min: 14.7   Max: 30.3
Current: 16.7

14.7
30.3
» ENDP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ENDP Guru Trades in Q1 2013

Richard Snow 51,040 sh (New)
Mario Gabelli 56,550 sh (New)
Louis Moore Bacon 135,000 sh (+80%)
Jeremy Grantham 45,430 sh (+22.78%)
Steven Cohen 2,673,898 sh (+19.16%)
John Hussman Sold Out
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
David Dreman Sold Out
Jim Simons Sold Out
Joel Greenblatt 313,273 sh (-12.52%)
» More
Q2 2013

ENDP Guru Trades in Q2 2013

John Griffin 6,800,000 sh (New)
Jim Simons 262,293 sh (New)
Paul Tudor Jones 300,000 sh (New)
Joel Greenblatt 440,490 sh (+40.61%)
Richard Snow 55,905 sh (+9.53%)
Jeremy Grantham 47,573 sh (+4.72%)
Louis Moore Bacon Sold Out
Mario Gabelli 43,350 sh (-23.34%)
Steven Cohen 6,024 sh (-99.77%)
» More
Q3 2013

ENDP Guru Trades in Q3 2013

Stanley Druckenmiller 527,000 sh (New)
Ray Dalio 14,272 sh (New)
Andreas Halvorsen 3,236,019 sh (New)
Steven Cohen 7,481 sh (+24.19%)
Joel Greenblatt 521,987 sh (+18.5%)
Richard Snow 58,555 sh (+4.74%)
John Griffin 7,000,000 sh (+2.94%)
Paul Tudor Jones Sold Out
Jim Simons 254,940 sh (-2.8%)
Mario Gabelli 41,050 sh (-5.31%)
Jeremy Grantham 17,450 sh (-63.32%)
» More
Q4 2013

ENDP Guru Trades in Q4 2013

Wallace Weitz 445,920 sh (New)
David Dreman 1,378 sh (New)
Steve Mandel 4,340,000 sh (New)
Jim Simons 1,005,693 sh (+294.48%)
Jeremy Grantham 53,382 sh (+205.91%)
Steven Cohen 17,467 sh (+133.48%)
John Griffin 8,000,000 sh (+14.29%)
Stanley Druckenmiller 527,000 sh (unchged)
Richard Snow Sold Out
Andreas Halvorsen Sold Out
Ray Dalio 13,272 sh (-7.01%)
Mario Gabelli 33,350 sh (-18.76%)
Joel Greenblatt 397,016 sh (-23.94%)
» More
» Details

Insider Trades

Latest Guru Trades with ENDP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Steve Mandel 2013-12-31 New Buy1.3%$43.64 - $67.25 $ 62.029%4340000
Wallace Weitz 2013-12-31 New Buy1%$43.64 - $67.25 $ 62.029%445920
John Griffin 2013-12-31 Add 14.29%0.7%$43.64 - $67.25 $ 62.029%8000000
Joel Greenblatt 2013-12-31 Reduce -23.94%0.18%$43.64 - $67.25 $ 62.029%397016
David Dreman 2013-12-31 New Buy0.01%$43.64 - $67.25 $ 62.029%1378
Joel Greenblatt 2013-09-30 Add 18.5%0.12%$36.3 - $45.61 $ 62.0254%521987
John Griffin 2013-09-30 Add 2.94%0.11%$36.3 - $45.61 $ 62.0254%7000000
Ray Dalio 2013-09-30 New Buy0.01%$36.3 - $45.61 $ 62.0254%14272
John Griffin 2013-06-30 New Buy3%$30.73 - $39.3 $ 62.0272%6800000
Joel Greenblatt 2013-06-30 Add 40.61%0.2%$30.73 - $39.3 $ 62.0272%440490
Mario Gabelli 2013-06-30 Reduce -23.34%$30.73 - $39.3 $ 62.0272%43350
John Hussman 2013-03-31 Sold Out 0.72%$25.06 - $31.66 $ 62.02112%0
David Dreman 2013-03-31 Sold Out 0.07%$25.06 - $31.66 $ 62.02112%0
Mario Gabelli 2013-03-31 New Buy0.01%$25.06 - $31.66 $ 62.02112%56550
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.60
ENDP's P/B is ranked lower than
72% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. ENDP: 13.60 )
ENDP' s 10-Year P/B Range
Min: 1.48   Max: 17.4
Current: 13.6

1.48
17.4
P/S 2.69
ENDP's P/S is ranked higher than
61% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. ENDP: 2.69 )
ENDP' s 10-Year P/S Range
Min: 1.03   Max: 6.1
Current: 2.69

1.03
6.1
PFCF 40.01
ENDP's PFCF is ranked higher than
58% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.86 vs. ENDP: 40.01 )
ENDP' s 10-Year PFCF Range
Min: 4.6   Max: 51.18
Current: 40.01

4.6
51.18
EV-to-EBIT -24.26
ENDP's EV-to-EBIT is ranked lower than
60% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. ENDP: -24.26 )
ENDP' s 10-Year EV-to-EBIT Range
Min: 3.9   Max: 27.3
Current: -24.26

3.9
27.3
PEG 24.90
ENDP's PEG is ranked lower than
65% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. ENDP: 24.90 )
ENDP' s 10-Year PEG Range
Min: 0.31   Max: 23.17
Current: 24.9

0.31
23.17

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.08
ENDP's Price/DCF (Projected) is ranked higher than
83% of the 346 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. ENDP: 1.08 )
ENDP' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 1.97
Current: 1.08

0.4
1.97
Price/Median PS Value 1.00
ENDP's Price/Median PS Value is ranked higher than
79% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. ENDP: 1.00 )
ENDP' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.78
Current: 1

0.4
1.78
Earnings Yield (Greenblatt) 2.30
ENDP's Earnings Yield (Greenblatt) is ranked lower than
52% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. ENDP: 2.30 )
ENDP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.7   Max: 25.4
Current: 2.3

3.7
25.4
Forward Rate of Return (Yacktman) 5.27
ENDP's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. ENDP: 5.27 )
ENDP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 62.2
Current: 5.27

2.9
62.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EPV.Germany, ENL.Canada
Endo Health Solutions Inc formerly Endo Pharmaceutical Holdings, was incorporated in the state of Delaware on November 18, 1997. The company operates as a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain. It has a portfolio of products that includes brand names such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and FortestaGel. Lidoderm (lidocaine patch 5%) was launched in September 1999. A topical patch product containing lidocaine, Lidoderm was the first FDA-approved product for the relief of the pain associated with post-herpetic neuralgia, a condition thought to result after nerve fibers are damaged during a case of Herpes Zoster (commonly known as shingles). Opana ER was launched during the second half of 2006 and had shown prescription growth since its launch until the 2012 supply disruption, which caused some patients to switch to other pain relief products. Opana ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. It launched Voltaren Gel in March 2008 upon closing of the license and supply agreement with Novartis AG and Novartis Consumer Health, Inc. Percocet launched in 1976, Percocet Tablets CII is approved for the treatment of moderate-to-moderately severe pain. The Company began shipping Frova Tablets upon closing of the license agreement with Vernalis in mid-August 2004. Frova is indicated for the acute treatment of migraine headaches in adults. Supprelin LA was launched in the U.S. in June 2007. Supprelin LA is a soft, flexible 12-month hydrogel implant based on its hydrogel polymer technology that delivers histrelin acetate, a gonadotropin releasing hormone (GnRH) agonist and is indicated for the treatment of central precocious puberty (CPP) in children. Vantas was launched in the U.S. in November 2004. Vantas is a soft, flexible 12-month hydrogel implant based on its hydrogel polymer technology that delivers histrelin acetate, a GnRH agonist and is indicated for the palliative treatment of advanced prostate cancer. The Company launched Valstar in September 2009. Valstar is a sterile solution for intravesical instillation of valrubicin, a chemotherapeutic anthracycline derivative. Fortesta Gel is a patented two percent (2%) testosterone transdermal gel and is a treatment for men suffering from hypogonadism, also known as low testosterone (Low T). The precision-metered dose delivery system can be accurately customized and adjusted to meet individual patient needs with the appropriate dose. The Company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, anesthesiology, oncology and primary care. The Company sells products directly to a limited number of pharmacy chains and through a limited number of wholesal

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide